Home

innoVitro is a seed stage start-up located at the University of Applied Sciences Aachen. Our core competence is the measurement of cellular forces, in particular of stem cell derived cardiomyocytes.

Cardiovascular diseases are the most common cause of death in the western world. Although mortality is steadily decreasing due to the continuous improvement of emergency medical care, late effects lead to a loss of life quality and high follow-up costs for the health care system. These late effects can be treated by medications with a strength-enhancing effect, which can significantly improve the quality of life of those affected. In the development and characterization of these drugs, the pharmaceutical industry has been dependent on animal experiments, which not only cost a great deal of money but also raise ethical concerns among public opinion.

innoVitro is working on the establishment of an in vitro cardiac muscle model based on CellDrum technology and human cardiac muscle cells.

The model is intended to be an alternative to animal experiments which will enable the qualitative and quantitative determination of substance effects on the contractility of myocardial cells. By using human stem cell derived cardiomyocytes, common issues with the translatability of pharmacological results from animal models to human physiology are avoided already in the preclinical phase of drug develomplent.